Latest News

Jesse L. Berry, MD, discusses prospective data on aqueous humor liquid biopsy in retinoblastoma and explains how molecular markers from the aqueous are beginning to guide recurrence risk, treatment intensity, and the workup of otherwise diagnostically inaccessible intraocular lesions.

Concurrent exudative disease, early intervention, and a rare masquerader complicate the classic picture of geographic atrophy.

Patient enrollment is complete in the the ASTRA phase 3 study AURN001 to treat corneal edema associated with corneal endothelial dysfunction.

Subretinal deposits are linked to worse surgical risks in patients with severe aortic stenosis and reduced systemic blood flow.

Talisa Forest (de Carlo), MD, discusses how dynamic complement biomarkers track with artificial intelligence-measured geographic atrophy progression.

K. Thiran Jayasundera, MD, MS, FACS, on how patient interviews shaped a tool capturing functional and psychological burdens overlooked by visual acuity.

One subretinal injection of medium-dose OCU410 gene therapy reduced geographic atrophy growth by up to 32%.

The meeting will include an Open Public Hearing.

Remigromig met its BRUNELLO primary end point in DME, with higher PDR and vitreous hemorrhage rates than ranibizumab.

EURETINA President Nicole Eter, MD, picks the sessions busy clinicians should follow at the 26th EURETINA Congress in Vienna, from durability data to AI. She also explains why early referral is still the most effective retina treatment.

Helena Noguera Nuñez, MD, discusses a prospective study of the TECNIS Odyssey IOL from ESCRS 2026.

Epithelial basement membrane dystrophy can affect premium IOL outcomes.

A checklist could help keep patients with geographic atrophy on track.